Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates

Transfusion

Volumn 48, Issue 2, 2008, Pages 304-313

  Terpstra, Fokke G ^a,b   Van't Wout, Angélique B ^b   Schuitemaker, Hanneke ^b   Van Engelenburg, Frank A C ^b   Dekkers, David W C ^b   Verhaar, Robin ^b   De Korte, Dirk ^b   Verhoeven, Arthur J ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PADGEM PROTEIN; PHOSPHATIDYLSERINE;

ARTICLE; BACILLUS CEREUS; BACTERIUM; CONTROLLED STUDY; ESCHERICHIA COLI; FELINE PANLEUKOPENIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; INFECTION; NONHUMAN; NONLIPID ENVELOPED VIRUS; PATHOGENESIS; PROTEIN EXPRESSION; PSEUDORABIES HERPETOVIRUS; SIMIAN VIRUS 40; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTE; TRANSMISSIBLE GASTROENTERITIS VIRUS; ULTRAVIOLET C RADIATION; ULTRAVIOLET IRRADIATION; VESICULAR STOMATITIS VIRUS; VIRUS;

BLOOD PLATELETS; DIARRHEA VIRUSES, BOVINE VIRAL; HUMANS;

EID: 38349108478     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01524.x     Document Type: Article

References (37)

1. te Boekhorst PA, Beckers EA, Vos MC, Vermeij H, van Rhenen DJ. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005 45 : 514 9.
2. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001 38 : 4 11.
3. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
4. Mohr H, Redecker-Klein A. Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang 2003 84 : 96 104.
5. Floyd RA, Schneider JE Jr, Dittmer DP. Methylene blue photoinactivation of RNA viruses. Antiviral Res 2004 61 : 141 51.
6. Caillet-Fauquet P, Di Giambattista M, Draps ML, Sandras F, Branckaert T, de Launoit Y, Laub R. Continuous-flow UVC irradiation: a new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19. J Virol Methods 2004 118 : 131 9.
7. Douki T, Cadet J. Individual determination of the yield of the main UV-induced dimeric pyrimidine photoproducts in DNA suggests a high mutagenicity of CC photolesions. Biochemistry 2001 40 : 2495 501.
8. Wei H, Cai Q, Rahn R, Zhang X. Singlet oxygen involvement in ultraviolet (254 nm) radiation-induced formation of 8-hydroxy-deoxyguanosine in DNA. Free Radic Biol Med 1997 23 : 148 54.
9. Pietersz RN, Loos JA, Reesink HW. Platelet concentrates stored in plasma for 72 hours at 22 degrees C prepared from buffycoats of citrate-phosphate- dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 1985 49 : 81 5.
10. Pietersz RN, de Korte D, Reesink HW, van den Ende A, Dekker WJ, Roos D. Preparation of leukocyte-poor platelet concentrates from buffy coats. III. Effect of leukocyte contamination on storage conditions. Vox Sang 1988 55 : 14 20.
11. Pietersz RN, de Korte D, Reesink HW, Dekker WI, van den Ende A, Loos JA. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989 56 : 145 50.
12. Loos H. Automation in blood component preparation. Prog Clin Biol Res 1986 211 : 333 41.
13. Fijnheer R, Veldman HA, van den Eertwegh AJ, Gouwerok CW, Homburg CH, Boomgaard MN, de Korte D, Roos D. In vitro evaluation of buffy-coat-derived platelet concentrates stored in a synthetic medium. Vox Sang 1991 60 : 16 22.
14. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis DR, De Korte D. Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion 1990 30 : 20 5.
15. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (Internet). CPMP/ BWP/268/95. London : The European agency for the evaluation of medicinal products 1996. [cited 1996 February 14]. Available from: http://emea.eu/pdfs/ human/bwp/026895en.pdf.
16. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95, Rev. 3. London : The European agency for the evaluation of medicinal products 2001. [cited 2001 January 25]. Available from: http://emea.eu/pdfs/human/bwp/026995en.pdf.
17. Terpstra FG, Parkkinen J, Tolo H, Koenderman AH, ter Hart HG, von Bonsdorff L, Torma E, Van Engelenburg FA. Viral safety of Nanogam(R), a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006 90 : 21 32.
18. German Federal requirements 'Requirements of validation studies for demonstrating the virus safety of medicinal products derived from human blood plasma' (Bundesanzeiger Nr. 84, Mai 1994). 1994.
19. Cochran WG. Estimation of bacterial densities by means of the "most probable number Biometrics 1950 6 : 105 16.
20. de Korte D, Curvers J, de Kort WL, Hoekstra T, van der Poel CL, Beckers EA, Marcelis JH. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006 46 : 476 85.
21. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 13th ed. Strasbourg : Council of Europe Press 2007.
22. Curvers J, van Pampus EC, Feijge MA, Rombout-Sestrienkova E, Giesen PL, Heemskerk JW. Decreased responsiveness and development of activation markers of PLTs stored in plasma. Transfusion 2004 44 : 49 58.
23. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003 43 : 526 35.
24. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006 90 : 279 85.
25. Boomgaard MN, Gouwerok CW, de Korte D, Loos JA. Platelets stored for 6 days in a polyolefin container in a synthetic medium with minimal plasma carry-over. Vox Sang 1994 66 : 18 24.
26. Kostelijk EH, Gouwerok CW, Veldman HA, de Korte D. Comparison between a new PVC platelet storage container (UPX80) and a polyolefin container. Transfus Med 2000 10 : 131 9.
27. Slieman TA, Nicholson WL. Artificial and solar UV radiation induces strand breaks and cyclobutane pyrimidine dimers in Bacillus subtilis spore DNA. Appl Environ Microbiol 2000 66 : 199 205.
28. Hanlin JH, Lombardi SJ, Slepecky RA. Heat and UV light resistance of vegetative cells and spores of Bacillus subtilis Rec-mutants. J Bacteriol 1985 163 : 774 7.
29. Romanovskaia VA, Rokitko PV, Malashenko I, Krishtab TP, Chernaia NA. [Sensitivity of soil bacteria isolated from the alienated zone around the Chernobyl Nuclear Power Plant to various stress factors]. Mikrobiologiia 1999 68 : 534 9.
30. Kallenbach NR, Cornelius PA, Negus D, Montgomerie D, Englander S. Inactivation of viruses by ultraviolet light. Curr Stud Hematol Blood Transfus 1989, 70 82.
31. Kurth J, Waldmann R, Heith J, Mausbach K, Burian R. Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation. Dev Biol Stand 1999 99 : 111 8.
32. Li Q, MacDonald S, Bienek C, Foster PR, Macleod AJ. Design of a UV-C irradiation process for the inactivation of viruses in protein solutions. Biologicals 2005 33 : 101 10.
33. Wang J, Mauser A, Chao SF, Remington K, Treckmann R, Kaiser K, Pifat D, Hotta J. Virus inactivation and protein recovery in a novel ultraviolet-C reactor. Vox Sang 2004 86 : 230 8.
34. Lytle CD, Sagripanti JL. Predicted inactivation of viruses of relevance to biodefense by solar radiation. J Virol 2005 79 : 14244 52.
35. Temin HM. Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci U S A 1993 90 : 6900 3.
36. Chiavetta JA, Escobar M, Newman A, He Y, Driezen P, Deeks S, Hone DE, O'Brien SF, Sher G. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003 169 : 767 73.
37. Pillonel J, Laperche S. [Trends in residual risk of transfusion- transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of nucleic acid testing]. Transfus Clin Biol 2004 11 : 81 6.